) transcriptional start site (TSS) proximal region in several human cancer cell lines was found by analyzation of ChIP-Seq database from UCSC Genome Browser (http://genome.ucsc.edu). However, whether the stabilization of YY1 by BCCIP impacts its recruitment in the BCCIP promoter region is unclear. Here, we present evidence that transcriptional regulation of YY1 on BCCIP is closely related to YY1 stability in HCT116 human colon cancer cells. YY1 stabilization was in turn regulated by BCCIP, suggesting the existence of a BCCIP-YY1 feedback loop in regulating BCCIP transcription by the YY1. Overexpression of BCCIP stabilized YY1 while knockdown of BCCIP reduced YY1 protein level. In addition, direct interaction between YY1 and BCCIP was confirmed by coimmunoprecipitation approach. Also, the N-terminus region of BCCIP, including the internal conserved domain (ICD), was responsible for binding with the amino acid 146-270 of YY1. More importantly, YY1 stability was related to the BCCIP/ICD domain-mediated YY1 ubiquitination pathway. Moreover, a limited BCCIP promoter region containing YY1 binding site (CCGCCATC) was tightly associated with the pGL4-BCCIP-Luc luciferase activity. In ChIP assays, shBCCIP lentiviral-mediated YY1 instability decreased recruitment of the YY1 at BCCIP TSS proximal region, which could not be restored by YY1 overexpression. Furthermore, knockdown of YY1 inhibited the binding of BCCIP itself at BCCIP promoter region proximal to TSS, demonstrating that transcriptional regulation of the YY1 on BCCIP can be modulated by BCCIP itself in a YY1-dependent fashion.
Introduction
The human BRCA2 and CDKN1A/p21-interacting protein (BCCIP) is an evolutionarily conserved nuclear protein composed of three important regions: a N-terminus acidic domain (NAD), internal conserved domain (ICD), and C-terminus variable domain (CVD) [1, 2] . In cells, two different transcripts encoding BCCIPa [322 aa (amino acids)] and BCCIPb (314 aa) isoforms are produced by alternative gene splicing [3] . Given that both isoforms share the NAD and ICD domains [2] , the functional similarity between them has been speculated. Consistent with this notion, both isoforms interact with p21 and breast cancer 2 (BRCA2) [3] [4] [5] . Either overexpression or depletion of BCCIP disrupts normal cell cycle progression and Abbreviations BCCIP, BRCA2 and CDKN1A/p21-interacting protein; CVD, C-terminus variable domain; ICD, internal conserved domain; NAD, N-terminus acidic domain; TSS, transcriptional start site; YY1, Yin Yang 1.
impairs G1-S checkpoint activation by affecting the expression level of p21 [6, 7] . In addition, knocking down BCCIP leads to defective DNA damage repair [8] and chromosomal instability [9, 10] . As an important cofactor for BRCA2 in its tumor suppressor function, BCCIP has been implicated in many fundamental cellular processes with obvious links to cancer. Abnormal expression of BCCIP has been found in some cancer cell lines and several cancer tissues such as renal cell carcinoma, ovarian cancer, and colorectal carcinoma [2, 3, 11] . Although the number of studies on BCCIP has increased in recent years, the precise mechanisms underlying its functions have remained unclear.
Yin Yang 1 (YY1), a member of the GLI-Kr€ uppel class of proteins, was first discovered as a DNA-binding protein [12] [13] [14] . Based on the fact that it contains both transcriptional activation domain and transcriptional repression domains, its versatile functions in gene transcription regulation were found [15, 16] . Numerous studies have confirmed that YY1 can initiate, activate, or repress gene transcription by recruiting different transcriptional cofactors to its activation or repression domain. For example, the recruitment of histone deacetylases, histone acetyltransferase p300, and p300/CBP-associated factor to YY1's transcriptional repression domain not only affects the acetylation status of YY1, but also promotes its transcriptional repression activity [17] . In contrast, YY1 recruits protein arginine N-methyltransferase 1 to mediate histone H4 arginine 3 methylation, which further causes gene activation [18] . In addition, the expression level of YY1 is much higher in a large number of cancers; therefore, YY1 is also considered to be a potential prognostic biomarker and therapeutic target [19, 20] .
Using a combination of biochemical purification and multidimensional protein identification technology mass spectrometry approaches, we previously verified that YY1 is tightly associated with the human ATPdependent INO80 (INO80) chromatin remodeling complex [21] . Subsequent studies have demonstrated that YY1 can recruit the INO80 complex to YY1-activated genes such as cell division cycle 6 (CDC6) and 78 kDa glucose-regulated protein precursor (GRP78). Simultaneously, binding of YY1 to its DNA sites on both CDC6 and GRP78 promoters requires the INO80 complex, suggesting that YY1 functions with INO80 together to activate transcription [22] . Recently, through DNA microarray analysis combined with small interfering RNA (siRNA) knockdown approaches, a set of target genes of the INO80/YY1 chromatin remodeling complex were obtained, among which BCCIP was selected as a potential target [23] .
Additionally, based on a database (ChIP-Seq) search from The University of California-Santa Cruz (UCSC) Genome Browser (http://genome.ucsc.edu), the restriction of YY1 at the BCCIP transcriptional start site (TSS) proximal region in A549 adenocarcinomic human alveolar basal epithelial cells, HepG2 human hepatocellular carcinoma cells, and HCT116 human colon cancer cells was found, suggesting the function of the YY1 in regulating BCCIP gene transcription. Consistent with this idea, our biochemical experiments further clarified that the human INO80/YY1 complex transcriptionally regulates BCCIP in cells [23] . Interestingly, during our experiments, we noticed that YY1 protein expression levels were regulated by BCCIP. Therefore, we hypothesized that the regulation of BCCIP on YY1 may conversely affect recruitment of the YY1 to the BCCIP promoter region. In an effort to resolve this issue, using a series of biochemical and biological experiment approaches, we present evidence that the positive-feedback regulation of BCCIP on the YY1 exists in HCT116 cells.
Results

BCCIP stabilized YY1 protein in HCT116 cells
To explore the stabilization of YY1 by BCCIP, we first examined the endogenous YY1 protein level in BCCIP-overexpressing cells. The results as shown in Fig. 1A , endogenous YY1 protein levels were clearly increased in BCCIPa-and BCCIPb-overexpressing cells at 48 h after transfection (quantified YY1 protein signals were shown in Fig. 1B ), although YY1 mRNA levels remained unchanged (Fig. 1C) . In addition, colocalization of endogenous BCCIP and YY1 in nucleus was found by immunofluorescent staining of cells (Fig. 1D) . To further investigate the role of BCCIP in stabilizing YY1, we established stably expressing shBCCIP cell lines using lentiviruses encoding shNT (nontargeting) or shRNA targeting BCCIP (shBCCIP-311 and shBCCIP-730) [9] . As expected, endogenous YY1 protein level in shBCCIP-expressing cells was clearly decreased compared to the shNT group (Fig. 1E, lanes 2-4) , however, the mRNA of YY1 was unchanged (Fig. 1F) , suggesting the role of BCCIP in stabilizing endogenous YY1 protein. Similarly, the decreased endogenous YY1 protein level was observed by fluorescent staining of cells in shBCCIPexpressing cells (Fig. 1G) .
To further confirm the function of BCCIP in stabilizing YY1, endogenous or exogenous YY1 protein levels were analyzed at different time points. As expected, compared to the shNT group, lower endogenous YY1 protein levels at different time point were detected in shBCCIP-expressing group after treating cells with 20 lgÁmL À1 cycloheximide (CHX), a protein synthesis inhibitor, for 0, 3, and 6 h, respectively ( Fig. 2A) . Quantified YY1 proteins are shown in Fig. 2B . Similar results were observed in cells transfected with Flag-YY1. Compared to the pcDNA3.1 vector group, higher YY1 protein levels were observed at 24, 36, and 48 h in the BCCIPa-and BCCIPbtransfected cells (Fig. 2C ). Quantified YY1 protein levels are shown in Fig. 2D . In CHX-exposed cells, Flag-YY1 protein was more stable and lasted longer in BCCIP-overexpressed cells compared those to the pcDNA3.1 vector group (Fig. 2E) BCCIP/NAD + ICD domain is the region of YY1 binding, it can be assumed that BCCIP/NAD + ICD plays an important role in stabilizing YY1. To confirm this hypothesis, BCCIP/ICD domain deletion mutants (BCCIPaΔICD and BCCIPbΔICD) were constructed (Fig. 4C ). As shown in Fig. 4D ,E, protein levels of both full-length YY1 (Fig. 4D , lanes 5-6 and 11-12) and YY1/146-270 (Fig. 4E , lanes 5-6 and 11-12) were dramatically decreased by cotransfecting BCCIPΔICDa and BCCIPΔICDb compared to BCCIP wild-type (BCCIPa/b, WT)-transfected groups, indicating the role of BCCIP/ICD domain in regulating YY1 stability.
Next, to determine whether the stabilizing effect of BCCIP/ICD domain on YY1 was mediated by the ubiquitin pathway, polyubiquitination (Ubi) of YY1 was determined by incubating the cells with MG132, a peptide aldehyde that effectively blocks the proteolytic activity of the 26S proteasome complex. The experiment was performed with Flag IP followed by immunoblot of ubiquitin. As shown in Fig. 5A , poly-Ubi of YY1 was observed in the presence of HA-ubiquitin and MG132 cells (lanes 2 and lane 6). However, YY1-Ubi was dose-dependently decreased when BCCIP was overexpressed (lane 3-4 and lane [7] [8] . To further confirm those results, subsequent experiments were performed as shown in Fig. 5B . The results showed that full-length BCCIP inhibited YY1-Ubi (Fig. 5B, lane 3 and 9) , which was reversed upon BCCIPaΔICD or BCCIPbΔICD transfection. Dose-dependent increases in YY1-Ubi were observed in both BCCIPaΔICD-and BCCIPbΔICD-transfected cells (Fig. 5B , lanes 4-6 and 10-12), suggesting that BCCIP/ICD domain may regulate the YY1 stability through ubiquitin-proteasome-mediated degradation pathway. On the other hand, the knockdown of BCCIP increased the Ubi of YY1, further suggesting that BCCIP may stabilize YY1 by affecting the degradation of YY1 (Fig. 5D , lane [5] [6] . Based on the fact that Smurf2 E3 ubiquitin ligase can also be combined with YY1 and degrade YY1, the effect of BCCIP on YY1-Ubi by Smurf2 was investigated. As shown in Fig. 5C , as expected, knockdown of Smurf2 with siRNA induced YY1 degradation (lanes 3-4, compared to lane 2), however, siSmurf2 did not reduce the increased YY1-Ubi in shBCCIP-expressing cells (lanes 7-8, compared to lane 6), suggesting that the effects of Smurf2 and BCCIP on the ubiquitinproteasome-mediated YY1 degradation pathway may not be a competitive regulatory mechanism.
Transcriptional regulation of BCCIP was associated with its ability to stabilize YY1 in HCT116 cells
Based on YY1 can bind to BCCIP promoter region [23] , we wondered how stabilizing the YY1 protein by BCCIP impacted the recruitment of the YY1 to the BCCIP promoter region. To this end, Re-ChIP assays using BCCIP and YY1 antibodies were performed. Designed primer sets for ChIP and Re-ChIP procedure are shown in Fig. 6A,B . Interestingly, the co-occupancy of YY1 and BCCIP at the region À0.3 kb upstream and +0.17 kb downstream of the BCCIP TSS was observed (Fig. 6C) . To know if the stability of YY1 by BCCIP regulates the binding of YY1 to BCCIP promoter region, YY1-ChIP was performed in shBCCIP-expressing cells (Fig. 6D) . As a result, the recruitment of YY1 at À0.3 kb upstream and +0.17 kb downstream of the BCCIP TSS but not +2.9 kb away from the BCCIP TSS was remarkably decreased (Fig. 6E) , indicating that the BCCIP-mediated instability of YY1 may adversely affect recruitment of the YY1 to the BCCIP promoter region. To address this hypothesis, YY1-ChIP was again performed after transient transfection of YY1 into shBCCIP-expressing cells. The exogenous YY1 protein is shown in Fig. 6F . Unexpectedly, overexpressing YY1 did not improve the recruitment of YY1 to the BCCIP promoter region (Fig. 6G) , suggesting that recruitment of YY1 to the BCCIP promoter may require the presence of BCCIP itself. With regards to this, quantitative real-time PCR (RT-qPCR) primer sets specific to different region were designed to measure BCCIP mRNA (Fig. 7A) . After confirming the specificity of primer sets by checking melting curve of the PCR products (Fig. 7B) , RT-PCR experiments were performed in BCCIP-transfected HCT116 cells. Exogenous BCCIP protein level was analyzed by western blot (WB; Fig. 7D ). As shown in Fig. 7C , after transfection of BCCIP plasmids, dramatic increases of CDS region of its mRNA was observed (top panel). Importantly, the mRNA level of BCCIP at 5 0 -UTR and 3 0 -UTR (including both BCCIPa and BCCIPb) also increased in a dose-dependent manner, demonstrating that overexpression of BCCIP can indeed enhance the transcription of the endogenous BCCIP mRNA (lower panel). Furthermore, to investigate whether BCCIP binds to and activates its own promoter in a YY1-dependent fashion, lentiviral-mediated shYY1 (shYY1-1, shYY1-2, and shYY1-3) stable cell lines were established (Fig. 7E) . Then, ChIP assays were performed to determine if YY1 knockdown impacted BCCIP binding to and activating its own promoter. Surprisingly, knockdown of YY1 not only reduced the recruitment of YY1 to the BCCIP promoter (Fig. 7F) , but also inhibited the binding of BCCIP itself at À0.3 kb upstream and +0.17 kb downstream of the TSS (Fig. 7G) . Specific sequences (YY1 binding site) in the BCCIP promoter region were associated with BCCIP luciferase activity It is worth noting that BCCIP expression is driven by a bidirectional promoter. As shown in Fig. 8A (top panel), BCCIP and UROS are separated by 277 bases. To determine if transactivation of BCCIP was associated with YY1 binding sites, six different regions from the BCCIP promoter (926 bp, 391 bp, 383ΔYY1 site, 272 bp, 77 bp, and 195 bp) with or without the YY1 binding site was subcloned into the pGL4 luciferase vector (Fig. 8A, lower panel) . Then pGL4-BCCIP-Luc plasmids containing different BCCIP promoter regions were tested in dual luciferase assays. As shown in Fig. 8B, compared to the basal level, the luciferase activity of pGL4-BCCIP-Luc containing 926 bp, 391 bp, and 272 bp of the promoter region clearly increased (columns 2-4). The pGL4-BCCIP-Luc which contained a 195 bp BCCIP promoter region without the YY1 binding sequence, completely lost luciferase activity (column 6). However, the luciferase activity of pGL4-BCCIP-Luc with a limited promoter region and YY1 binding sequence (77 bp) retained weak luciferase activity (column 5). Thus, simply removing the YY1-binding sequence (pGL4-BCCIP-ΔYY1site) did not completely abolish BCCIP reporter gene activity (Fig. 8C) , suggesting that a limited BCCIP promoter region containing the YY1-binding site was required for the BCCIP reporter gene activity in cells. To further clarify whether YY1 binds directly to specific sequence (CCGCCATC) containing nucleosomes mentioned above, biotinylated DNA fragments (BCCIP promoter region with or without YY1 binding site) and recombinant human histone octamers were used to reconstitute nucleosomes in vitro (Fig. 8D) . Selected histones in reconstituted nucleosomes were detected by western blotting with indicated histone antibodies after biotin-precipitation (Biotin IP; Fig. 8E,  lane 2) . Then, chromatin binding assays were performed by incubating recombinant nucleosomes and purified His-Flag-YY1 protein from insect cells at room temperature for 2 h. As shown in Fig. 8F, YY1 proteins that bound to recombinant nucleosomes which contain the YY1 binding sites were visualized by western blotting with anti-Flag antibody in the biotin-IP reaction (lane 2). However, it was difficult to detect YY1 proteins from ΔYY1 site-nucleosomes after biotin IP (lane 5), suggesting the role of the YY1-binding site in recruiting YY1 to the BCCIP promoter.
Discussion
In this study, using a series of in vitro and in vivo experimental approaches we demonstrated that BCCIP maintains YY1 protein stability in HCT116 cells by directly binding to it. This stability not only impacts its accessibility to DNA, but also affects its ability to transcriptionally regulate BCCIP.
Yin Yang 1 is a multifunctional protein that can act as transcriptional repressor or activator in different cell types and at different developmental stages [12] . There are two possibilities on this issue: one is that the protein itself is post-translationally modified in a cellspecific fashion; the other is that the function of YY1 is dependent on the bioavailability of cofactors [24] . For example, YY1 can promote its transcriptional repression activity by recruiting histone deacetylases, histone acetyltransferase p300, and p300/CBP-associated factor to YY1's transcriptional repression domain [17] . While YY1 causes gene activation by recruiting protein arginine N-methyltransferase 1 to YY1's transcriptional activation domain [18] . It has been known that both BCCIP and YY1 are implicated in various essential cellular functions with obvious links to cancer such as gene regulation, genome maintenance, and organism development [9, 10, 15, 25, 26] . In our experiments, BCCIP binds directly to the residues 146-270 of YY1 and stabilizes YY1 protein in HCT116 colon cancer cells. Transient transfection of pLVX-shBCCIP increased YY1-Ubi levels, in contrast, the YY1-Ubi was decreased in BCCIP-overexpressed cells, suggesting the roles of BCCIP in regulating YY1 stability through the ubiquitin-proteasome-mediated degradation pathway (Figs 4 and 5) . Noting that Smurf2 E3 ubiquitin ligase can also bind to the sequences 195-295 of YY1, induce the polyUbi of YY1 and shorten the half-life of YY1 protein [27, 28] . However, there is no direct interaction between two proteins, although the binding region of two proteins to YY1 overlaps (data not shown). Also, knocking down Smurf2 with siRNA could not reduce shBCCIP-mediated increase of YY1-Ubi, suggesting that BCCIP and Smurf2 have their own regulatory mechanisms for the Ubi of YY1.
Based on the analysis of our gene expression profiles and data from UCSC Genome Browser database (ChIP-Seq), BCCIP was selected as a potential target gene of YY1. This hypothesis was confirmed by our ChIP experimental results that YY1 can be recruited at BCCIP TSS proximal region, demonstrating YY1 function in regulating BCCIP expression. In addition, the protein stability of YY1 is often modulated by its associated proteins, which in turn impacts its accessibility to DNA, which further affects its function as a cofactor that recruits other proteins or complexes to the promoter region of target genes. In our experiments, lentiviral shBCCIP-mediated YY1 instability decreased its ability to recruit the YY1 to the BCCIP promoter, which could not be reversed by YY1 overexpression, suggesting the presence of a BCCIP-YY1 feedback mechanism in cells. Considering the interaction between YY1 and BCCIP, there is a possibility that YY1 and BCCIP are corecruited to the promoter region of BCCIP. This conjecture was then confirmed by Re-ChIP experiments with YY1-and BCCIP-specific antibodies. Moreover, knocking down either YY1 or BCCIP affected the recruitment of YY1/BCCIP complex to the BCCIP promoter region, demonstrating that together with YY1, BCCIP is involved in its own transcriptional regulation as well. Since the mRNA level of BCCIP at 5 0 -UTR and 3 0 -UTR was increased in a dose-dependent manner after overexpressing BCCIP in HCT116 cells.
The DNA cognate sequence of YY1 is often present within 1 kb upstream of the transcriptional initiation site of many genes [16] . The YY1-binding site (CCGCCATC) on BCCIP was identified at À0.26 kb upstream of the BCCIP TSS [3] , and recombinant YY1 protein can only bind to the reconstituted nucleosomes containing YY1-binding site. However, in gene reporter assays, although the YY1-binding site was closely related to pGL4-BCCIP-Luc luciferase activity, simply removing the YY1-binding sequence (pGL4-BCCIP-ΔYY1site) did not completely abolish BCCIPLuc luciferase activity, suggesting that a limited BCCIP promoter region containing the YY1-binding site was required for the BCCIP transactivation. It should be mentioned that BCCIP and UROS genes share an intergenic bidirectional promoter (277 bases) for their expression, suggesting the existence of more complicated mechanisms in regulating YY1/BCCIP binds to and activates BCCIP gene expression.
In this study, we demonstrate that BCCIP binds to and activates its promoter in a YY1-dependent fashion in HCT116 cells. However, some questions remain unclear about this positive-feedback BCCIP mechanism: (a) What is the precise mechanism by which BCCIP stabilizes YY1? (b) Does the BCCIP-mediated YY1-BCCIP-feedback mechanism affect the conformation of the YY1-containing INO80 chromatin remodeling complex? (c) How do BCCIP and YY1 jointly play a role in tumorigenesis? Additionally, both YY1 and BCCIP are involved in the regulation of p53, so further studies are warranted to investigate whether the coordination between BCCIP and YY1 is implicated in p53-mediated functions. 
Materials and methods
Antibodies
Reverse transcription PCR (RT-PCR)
Isolation of total RNA and reverse transcription (cDNA synthesis) were performed using RNAiso Plus (D9109; Takara, Tokyo, Japan) and the PrimeScript 1st Strand cDNA Synthesis Kit (Takara) as described [23] . YY1, BCCIP, and GAPDH mRNA were measured by RT-qPCR with Eco TM Real-Time PCR System (Illumina, Gene Company Limited, Hong Kong, China). The PCR reactions were conducted as previously described [23] . The specific mRNA was measured by qPCR with the following RT-primer sets: YY1, 5 0 -CCCTCATAAAGGCTGCACAA-3 0 (forward) and 
CoIP of endogenous proteins
Prepared whole-cell extract from HCT116 cells was applied for CoIP experiments using 2 lg of YY1 and BCCIP antibodies.
CoIP of recombinant proteins
His-Flag-tagged full length of YY1 was subcloned into pBacPAK8. Recombinant baculoviruses were generated with the BacPAK baculovirus expression system (Clontech Laboratories, Inc., Mountain View, CA, USA). Sf21 cells were then infected with the recombinant baculoviruses. 60 h after infection, recombinant YY1 protein was purified with anti-Flag (M2)-agarose affinity chromatography. While the full length of BCCIPa and BCCIPb were subcloned into pGEX6P-1 that contains for expression in bacteria. Expressed GST-fused BCCIP protein was purified with GST Sepharose, and the final recombinant BCCIP proteins were obtained by removing GST tag using PreScission Protease.
shRNA knockdown vector. The lentivirus system includes the packing regions (Rev. VSV-G, RRE) and Lenti-X region that uses puromycin as a selection marker. The 293T cell line was selected for optimizing the Lentivirus production. To obtain high-titer supernatants of infectious lentivirus, 293T cells were transfected with Lenti-X (800 ng) and packing plasmids (RRE 400 ng, Rev 140 ng, VSV-G 200 ng) using 4 lL poly (ethylenimine). After 48 h, the medium was harvested to infect the target cells for at least 16 h. Then, 2 lgÁmL À1 puromycin was used to select the BCCIP or YY1 knockdown stable cell line. The shRNA sequences targeted to BCCIP and YY1 are referenced in previous reports [9, 29] .
Luciferase reporter assay
The BCCIP promoter region (926 bp, À724 to +202 bp; 391 bp, À330 to +61 bp; 383 bp with deletion of YY1 binding sequences; 272 bp, À277 to À5 bp; 195 bp, À200 to À5 bp; 77 bp, À277 to À200 bp) was introduced into the pGL4-Luc vector. The luciferase reporter assay was conducted as described [23] . The transactivation activity of pGL4-BCCIP was determined by measuring firefly and Renilla luciferase activities using the Dual-Luciferase Reporter assay kit (Promega, Madison, WI, USA) and by normalizing to Renilla luciferase.
Immunofluorescence staining
Immunofluorescence staining was done as described previously [23] . Cells were incubated with BCCIP (1 : 250) and YY1 (1 : 100) primary antibodies at 37°C for 1 h, and then stained with FITC-or TRITC-conjugated secondary antibodies (rabbit/green: 1 : 300, sc-2012; mouse/green: 1 : 300, sc-2010). Cell nuclei were stained with DAPI containing Vectashield (H-1200; Vector Laboratories, Inc., Burlingame, CA, USA). Fluorescence images were observed with the Olympus BX40F Microscope (Olympus Co., Tokyo, Japan).
ChIP assay
One 10 cm dish (~2 9 10 7 ) of HCT116 cells was grown to 80% of confluence and used for each ChIP assay. ChIP assay was conducted essentially as described using INO80NL and YY1 antibodies. ChIP DNA was subjected to qPCR. Each experiment was performed 2-3 times. Both ChIP and IgG-antibody signals were normalized to the total input. Three primer sets for qPCR on the promoter region of BCCIP were designed: BCCIP À0. 
Preparation of recombinant nucleosomes
A 391 bp DNA fragment (BCCIP promoter region with or without YY1 binding sequence) was generated by PCR using biotinylated oligonucleotides as primers (forward: 5 0 -CTAGCAAAATAGGCTGTCCC-3 0 ; reverse: 5 0 -GTCTT CGAGTGGGTAGAATG-3 0 ) and the plasmid PGL4-BCCIP as template. Nucleosomes were then reconstituted with recombinant human histone octamers and amplified DNA according to the protocol described by Owen-Hughes et al. [30] . The assembled reaction was mixed with an equal volume of avidin-coupled Dynabeads (Invitrogen), and the recombinant nucleosomes were prepared as described previously [30] .
